|Abstract Title:||Simultaneous determination of lovastatin and its metabolite in rat plasma by liquid chromatography tandem mass spectrometry|
|Session Choice:||Comprehensive Chromatography - The State of the Art|
|Presenter Name:||Mrs Wen-Ya Peng|
|Company/Organisation:||National Yang-Ming University|
|Country:||Taiwan, Republic of China|
Abstract Information :
Lovastatin is used by millions of individuals for the effect of lowering blood cholesterol. A specific and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method had been developed and validated for the simultaneous analysis of lovastatin and lovastatin acid. Plasma samples were processed with a liquid-liquid extraction method, followed by chromatographic separation using an Phenomenex® Gemini C18(150 mm x 2.0 mm I.D, 5 µm particles) column. The gradient elution was used at a flow rate of 0.2 mL/min with a mobile phase of methanol and 0.1% formic acid (90:10, v/v). Multiple reaction monitoring (MRM) was employed for quantification with electrospray ion source polarity in positive mode. The monitored transitions were m/z 405.4 to 199.2 for lovastatin and m/z 423.3 to 300.2 for lovastatin acid. The method was validated and lower limits of quantification (LLOQ) were determined at 1 ng/mL and 10 ng/mL for lovastatin and lovastatin acid. Linearity coefficient of R2>0.995 were observed over wide range of 1 ng/mL to 100 ng/mL and 10 ng/mL to 1000 ng/mL of lovastatin and lovastatin acid in rat plasma. The mean recovery for lovastatin and lovastatin acid in rat plasma were 60.13%±2.93% and 58.10%±2.36%. The mean Matrix effect for lovastatin and lovastatin acid in rat plasma were 92.94%±5.72% and 98.45%±6.01%.
Acknowledgements: This work was supported by a grant from the Ministry of Science and Technology of Taiwan (MOST105-2113-M-010-004).